GlassScriptPhysician profile
Rohan Mankikar
NPI 1851683445
$5,093.82
in general payments reported to CMS, 2019-2025
21 companies · $2,055 in 2025
The $2,055 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $12.70 · 2022: $182 · 2023: $1,032 · 2024: $1,441 · 2025: $2,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,527.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,198.24 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $927.41 | 2023-2025 | Tezspire, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $754.50 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Philips North America LLC | $388.57 | 2025 | Vest Therapy Und |
| Verona Pharma, INC. | $319.10 | 2025 | Ohtuvayre |
| Electromed, INC. | $295.14 | 2023-2025 | Smartvest |
| Genzyme Corporation | $195.92 | 2024-2025 | |
| Baxter Healthcare | $180.54 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Amgen INC. | $146.24 | 2023-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $126.65 | 2024-2025 | Dupixent |
| Pfizer INC. | $105.70 | 2019-2025 | |
| Hikma Pharmaceuticals USA | $101.45 | 2023-2024 | Ryaltris |
| Merck Sharp & Dohme LLC | $96.07 | 2019-2025 | Gardasil 9, Gardasil, Belsomra |
| Genentech USA, INC. | $89.65 | 2019 | |
| Insmed, INC. | $55.69 | 2025 | Brinsupri, Arikayce |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $20.95 | 2023 | Quviviq |
| Grifols USA, LLC | $20.00 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.30 | 2023 | Gvoke Hypopen |
| Phadia US INC. | $19.06 | 2024 | Immunocap |
| Daiichi Sankyo INC. | $17.68 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohan Mankikar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.